Will lead launch of drug to prevent chemotherapy-induced nausea
AP Pharma has appointed the former global head of oncology at Bayer Healthcare Robert Rosen as its new senior VP and chief commercial officer.
In this role he will lead efforts at the US-based specialty pharma company to launch APF530 – AP Pharma's lead product candidate for the prevention of chemotherapy-induced nausea and vomiting.
If the drug does successfully make it onto the market, Rosen will also serve as a director of the company, AP Pharma said.
“We are delighted to bring Robert on to the AP Pharma management team,” said John Whelan, president and CEO of the company. “Robert's deep and extensive experience commercialising oncology drugs will be instrumental as we enter the commercialisation phase of the company.”
This experience includes his time leading Bayer's efforts in cancer from 2005 to 2011.
During this time, he led the launch of Nexavar (sorafenib), which made more than $1bn last year, for the treatment of renal cell carcinoma and hepatocellular carcinoma.
Rosen also led premarket activities for Stivarga (regorafenib) in its indications for gastrointestinal stromal tumours and colon cancer, as well as for alpharadin in prostate cancer.
Prior to joining Bayer, Rosen was VP of the oncology business unit at Sanofi-Synthèlabo, where he helped develop Sanofi's cancer footprint in the US with the launch of Eloxatin (oxaliplatin) for colon cancer.